Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
- Registration Number
- NCT06062823
- Lead Sponsor
- National University Hospital, Singapore
- Brief Summary
The goal of this clinical trial is to explore the efficacy of afatinib in NSCLC harbouring EGFR PACC mutation subtype. The main question it aims to answer is:
Afatinib is active in patients with advanced NSCLC harbouring EGFR PACC mutation subtype.
Participants will undergo screening, follow by treatment if eligible for study participation and then enter follow up phase after study medication has stopped. Patients will take afatinib 40mg daily continuously, until the development of progressive disease or meeting discontinuation criteria. A treatment cycle is defined as 28 days.
- Detailed Description
This is a multi-center, open-label, phase II study of patients with stage IIIb-IV NSCLC harbouring EGFR PACC mutations.
Before taking the study drug, patients will need to undergo baseline assessments to ensure that they are eligible for the study. Then they will enter treatment period, where afatinib 40mg will be administered daily continuously, until the development of progressive disease or meeting discontinuation criteria. A discontinuation visit will be performed if patients stopped study drug for any reason. Thereafter, patients will be placed on Follow Up visit.
Clinical assessment, routine blood tests and routine imaging:
Physical examinations, imaging, and blood tests will be performed during baseline assessment, on the first day of each treatment cycle, after patients have completed the study and when clinically required by the treating physician. Patients will need to visit the doctor's office approximately 1-2 times every 4 weeks when they are receiving active treatment during the course of the study. More frequent visits may be needed as clinically indicated by the treating physician.
Treatment procedure:
Afatinib will be taken once a day at approximately the same time each day initially starting at a dose of 40mg. Afatinib must be taken on an empty stomach (at least one hour before or at least two hours after a meal).
Research Blood samples:
Blood samples for research will be taken at baseline, before starting cycle 3 and at the time of cancer progression. The estimated total volume of research blood that will be drawn is 10mL (2-3 teaspoons) each time for a total of 30mL.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 35
-
Histological or cytologically confirmed NSCLC.
-
No prior systemic therapy for advanced stage disease.
-
Presence of a PACC mutation (detected either in blood or tumour) as defined by Robichaux et al (24). Compound mutations classified as PACC mutations are permitted (24).
-
The presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (28).
-
Estimated life expectancy of at least 3 months.
-
ECOG performance status 0-1.
-
Age ≥21 years old.
-
Have adequate organ and hematologic function, as defined by:
- Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤3.0 x upper limit of normal (ULN) or ≤5 times ULN if related to liver metastases.
- Total serum bilirubin ≤1.5 × ULN (<3.0 × ULN for patients with Gilbert syndrome)
- Creatinine clearance >=45mL/min (Cockcroft Gault)
- Absolute neutrophil count ≥1.5 × 10^9/L
- Platelet count ≥100 × 10^9/L
- Hemoglobin ≥ 9.0 g/dL
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
-
For female patients of childbearing potential, have a negative pregnancy test documented ≤ 14 days prior to start of study medication.
-
Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use a highly effective form of contraception with their sexual partners during the dosing period and for a period of at least 4 months after the end of treatment. Evidence of non-child-bearing potential is fulfilled by one of the following criteria at screening:
- The post-menopausal period defined as age ≥50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
- Women <50 years old they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range.
- Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not a tubal ligation
-
Signed written informed consent.
- Prior EGFR TKI therapy.
- Prior chemotherapy for Stage IIIB/IV adenocarcinoma of the lung. Neo-/adjuvant chemotherapy, CT-RT or RT is permitted if it has been elapsed for ≥12 months prior to disease progression.
- Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non melanoma skin cancer or cervical cancer in situ; definitively treated non metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
- Known leptomeningeal carcinomatosis.
- Unstable spinal cord compression/brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the start of study treatment. For patients with brain metastases, gamma knife or stereotactic brain surgery is allowed prior to study treatment.
- Symptomatic and untreated spinal cord compression.
- Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: myocardial infarction within 6 months prior to study enrolment; unstable angina within 6 months prior to study enrolment; congestive heart failure within 6 months prior to study enrolment; history of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician; any history of clinically significant ventricular arrhythmia; prolonged QTc.
- Had a cerebrovascular accident or transient ischemic attack within 6 months prior to enrolment.
- Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Minor surgery is allowed.
- Radiotherapy to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks before the study entry.
- Inability to swallow oral medication.
- Refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection that would preclude adequate absorption of afatinib.
- Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.
- Have an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.
- Have a known history of human immunodeficiency virus infection or active hepatitis B or C infection, active tuberculosis.
- Have a known or suspected hypersensitivity to afatinib or its excipients.
- Are pregnant, planning a pregnancy, or breastfeeding.
- Males and females of reproductive potential who are not using an effective method of contraception and females who are pregnant or breastfeeding or have a positive serum pregnancy test prior to study entry.
- Previous allogeneic bone marrow transplant.
- Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the study treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Afatinib Afatinib 40 MG Afatinib given as monotherapy daily in a 28-days cycle.
- Primary Outcome Measures
Name Time Method Objective response rate At baseline and every 8 weeks for the first 6 cycles, every 12 weeks from cycle 7 to 12 and every 16 weeks from cycle 13 onwards (each cycle is 28 days) Defined as best overall response (Complete Response or Partial Response) across all assessment time-points according to RECIST criteria v1.1
- Secondary Outcome Measures
Name Time Method Progression free survival within 4 weeks from starting treatment and every 8 weeks for the first 6 cycles, every 12 weeks from cycle 7 to 12 and every 16 weeks from cycle 13 onwards (each cycle is 28 days) Defined as the time from the date of study enrolment to the first date of documented disease progression
Time to treatment failure 48 months Defined as the time from afatinib treatment to the time of treatment discontinuation for any reason including disease progression, treatment toxicity, and death
Number of participant with treatment related toxicities 48 months Toxicities will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading Version 5
Overall survival 48 months Defined as the time from the date of randomisation until documented progression (according to RECIST v1.1) or death
Duration of response every 8 weeks for the first 6 cycles, every 12 weeks from cycle 7 to 12 and every 16 weeks from cycle 13 onwards (each cycle is 28 days) Defined as the time from first documented Complete Response or Partial Response to the time of radiological progression or death, whichever occurs earlier.
Trial Locations
- Locations (1)
National University Hospital
🇸🇬Singapore, Singapore